Dr. Jeffrey Jones on Idelalisib Combinations in CLL

Jeffrey Jones, MD
Published: Wednesday, Jul 22, 2015



Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses idelalisib (Zydelig) combinations in CLL.

Although idealisib has been proven effective as a single-agent therapy, sustained remissions that eventually lead to the discontinuation of therapy may require combination therapies, says Jones.

Idealisib has been studied in combination with monoclonal antibodies, chemotherapy, and most recently novel targeted therapies like ofatumumab (Arzerra). Ofatumumab was shown to improve progression-free survival by 8 months in combination with idealisib compared to ofatumumab alone in a phase III randomized, controlled study.
 
SELECTED
LANGUAGE


Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses idelalisib (Zydelig) combinations in CLL.

Although idealisib has been proven effective as a single-agent therapy, sustained remissions that eventually lead to the discontinuation of therapy may require combination therapies, says Jones.

Idealisib has been studied in combination with monoclonal antibodies, chemotherapy, and most recently novel targeted therapies like ofatumumab (Arzerra). Ofatumumab was shown to improve progression-free survival by 8 months in combination with idealisib compared to ofatumumab alone in a phase III randomized, controlled study.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x